Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:AURANASDAQ:DBVTNASDAQ:HUMA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.69-1.4%$0.72$0.20▼$3.02$82.36M0.692.65 million shs526,311 shsAURAAura Biosciences$7.22+2.0%$7.97$5.99▼$13.50$357.39M0.36168,491 shs116,066 shsDBVTDBV Technologies$0.68-1.1%$0.78$0.65▼$2.37$131.54M0.7550,065 shs41,558 shsHUMAHumacyte$3.99+2.3%$3.51$1.96▼$5.60$475.13M1.461.12 million shs686,965 shsBeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-2.08%+1.17%+5.87%+16.19%-74.37%AURAAura Biosciences-0.28%+0.28%-7.21%-6.72%-21.33%DBVTDBV Technologies+3.68%-0.09%-11.19%-22.97%-56.64%HUMAHumacyte+2.09%+8.64%+27.04%+34.02%+17.47%Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.7464 of 5 stars3.01.00.04.72.62.50.6AURAAura Biosciences1.3965 of 5 stars3.50.00.00.02.51.70.6DBVTDBV Technologies2.2288 of 5 stars3.23.00.00.00.03.31.3HUMAHumacyte2.2622 of 5 stars3.44.00.00.00.62.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,957.97% UpsideAURAAura Biosciences3.00Buy$21.00190.86% UpsideDBVTDBV Technologies2.33Hold$5.00633.14% UpsideHUMAHumacyte2.75Moderate Buy$8.00100.50% UpsideCurrent Analyst RatingsLatest ATRA, DBVT, HUMA, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2024HUMAHumacyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.003/26/2024HUMAHumacytePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.003/25/2024HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$8.57M9.61N/AN/A($0.97) per share-0.71AURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/ADBVTDBV Technologies$15.73M8.36N/AN/A$0.73 per share0.93HUMAHumacyte$1.57M302.63N/AN/A$0.13 per share30.69Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)AURAAura Biosciences-$76.41M-$1.92N/AN/AN/AN/A-42.20%-36.66%5/9/2024 (Estimated)DBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)HUMAHumacyte-$110.78M-$1.07N/AN/AN/AN/A-199.62%-61.45%5/10/2024 (Estimated)Latest ATRA, DBVT, HUMA, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/27/2024Q4 2023AURAAura Biosciences-$0.39-$0.50-$0.11-$0.50N/AN/A3/22/2024Q4 2023HUMAHumacyte-$0.25-$0.24+$0.01-$0.24$0.10 millionN/A 3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A0.720.65AURAAura BiosciencesN/A18.7618.76DBVTDBV TechnologiesN/A4.264.26HUMAHumacyte1.204.524.52OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%AURAAura Biosciences96.75%DBVTDBV Technologies71.74%HUMAHumacyte44.71%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%AURAAura Biosciences5.90%DBVTDBV Technologies0.71%HUMAHumacyte23.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableAURAAura Biosciences8849.50 million46.58 millionNot OptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableHUMAHumacyte183119.08 million91.58 millionOptionableATRA, DBVT, HUMA, and AURA HeadlinesSourceHeadlineA U.S. Senator Just Bought this Tiny Stock – It’s Up 15% Todaymsn.com - April 20 at 2:59 PMU.S. Senator trading alert: This stock surged 40% within 4 days of disclosurefinbold.com - April 19 at 2:16 PMHere’s why the Humacyte (HUMA) stock price is pumpinginvezz.com - April 19 at 2:04 PMThis US politician just made a really suspicious tradefinbold.com - April 19 at 4:24 AMA U.S. Senator Just Bought this Tiny Stock - It's Up 15% Todaymsn.com - April 18 at 7:56 PMAlly Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursdaybenzinga.com - April 18 at 2:55 PMFormer HHS secretaries: Congress should adopt site-neutral payments for health carestatnews.com - April 18 at 2:55 PMTuberville’s Trading Raises Questions: Senator Sells Put Options, Invests in Small Biotech Tied to Ukraine-Russia Conflictmsn.com - April 18 at 2:55 PMShort Interest in Humacyte, Inc. (NASDAQ:HUMA) Expands By 5.3%americanbankingnews.com - April 18 at 4:28 AMSolventum appoints Shirley Edwards to board of directorsmedtechdive.com - April 17 at 11:14 PMU.S. Senator Tommy Tuberville Just Reported a Purchase of $HUMA stockca.investing.com - April 17 at 11:14 PMHumacyte, Inc. (HUMA) Interactive Stock Chart - Yahoo Financefinance.yahoo.com - April 15 at 11:26 PMOppenheimer Keeps Their Buy Rating on Humacyte (HUMA)markets.businessinsider.com - April 8 at 4:08 PMResearch Analysts Set Expectations for Humacyte, Inc.'s FY2024 Earnings (NASDAQ:HUMA)marketbeat.com - April 4 at 9:14 AMHumacyte's (HUMA) Overweight Rating Reiterated at Cantor Fitzgeraldmarketbeat.com - April 1 at 9:10 AMShort Interest in Humacyte, Inc. (NASDAQ:HUMA) Declines By 36.5%marketbeat.com - March 29 at 10:48 AMHumacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024globenewswire.com - March 26 at 4:05 PMHumacyte’s Strong Outlook: Buy Rating Affirmed Amid Advancements and Market Opportunitymarkets.businessinsider.com - March 23 at 6:39 PMQ4 2023 Humacyte Inc Earnings Callfinance.yahoo.com - March 23 at 8:42 AMBuy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth Potentialmarkets.businessinsider.com - March 22 at 10:41 PMHUMA Stock Earnings: Humacyte Meets EPS for Q4 2023investorplace.com - March 22 at 11:53 AMHumacyte GAAP EPS of -$0.24 in-linemsn.com - March 22 at 10:12 AMHumacyte Fourth Quarter and Year End 2023 Financial Results and Business Updateglobenewswire.com - March 22 at 7:00 AMWhat Wall Street expects from Humacyte's earningsmarkets.businessinsider.com - March 21 at 7:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsCaterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesApril 25, 2024 10:36 AMView Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower PricesFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains ImminentCan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?All Headlines Company DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.Aura BiosciencesNASDAQ:AURAAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.HumacyteNASDAQ:HUMAHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.